The high cost of prescription drugs continues to burden patients and taxpayers. Surveys have shown that about three in ten adults do not take their medicines as prescribed because of the cost. Policymakers and regulators continue to explore various policies and enforcement actions to address the key drivers of high drug prices, address market distortions, and ensure patients and their families can access life-saving treatments. At the same time, challengers are actively pursuing several strategies, including litigation, that could frustrate state and federal measures that address prescription drug affordability.
Tracked Litigation
1:24-cv-02609
Amneal Pharmaceuticals LLC v. Weiser et al.
0:23-cv-02024
Association for Accessible Medicine v. Ellison
1:25-cv-3452
Amgen, Inc. et al. v. Mizner et al. II
3:25-cv-01757
Association for Accessible Medicines v. Boughton et al.
3:25-cv-01724
Healthcare Distribution Alliance v. Boughton et al.
1:24-cv-00544
Association for Accessible Medicines v. Raoul
Inactive Case
1:21-cv-00691
Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals
Inactive Case
Inactive Case
1:23-cv-02584